ANTX

AN2 THERAPEUTICS, INC.

ANTX · CIK 0001880438 · Annual (10-K) · Last 3 years

Financial Trends

Revenue
20222024
Net Income−$51M
20222024
Operating CF−$49M
20222024
Free Cash Flow
20222024

Income Statement

MetricFY 2024FY 2023FY 2022
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.0B$0.1B$0.0B
SG&A Expense
Operating Income$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.72$-2.74$-2.79
EPS (Diluted)$-1.72$-2.74$-2.79

Balance Sheet

MetricFY 2024FY 2023FY 2022
Total Assets$0.1B$0.1B$0.1B
Current Assets$0.1B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024FY 2023FY 2022
Operating Cash Flow$-0.0B$-0.1B$-0.0B
Investing Cash Flow$0.1B$-0.0B$-0.0B
Capital Expenditures
Financing Cash Flow$0.0B$0.1B$0.1B